Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E.
Target Price
The average target price of XBRANE.ST is 12 and suggests 92% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell